HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Switch For Naloxone Finding Interest Among Sponsors

Executive Summary

With FDA 'si label comprehension study near completion, sponsors seem more positive about OTC versions of naloxone products. FDA has made clear it is interested in switching the product from Rx-only but had trouble generating sponsor desire to develop it.

Advertisement

Related Content

US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals
FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals
Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
Opioid Prescribing Guidelines Will Be More Template Than Commandment
Naloxone Model OTC Label Expected From US FDA As Part Of Opioids Strategy
Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS139943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel